{"success":true,"data":{"pressRelease":{"id":"156787","rtpr_id":"nACSs0dTza-20260930","ticker":"AIMD","exchange":"NASDAQ","all_tickers":["AIMD","AIMDW"],"title":"Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment","author":"ACCESSWIRE","published_at":"2026-09-30T13:00:01.168Z","article_body":"HOUSTON, TX / ACCESS Newswire (https://www.accessnewswire.com/) / September\n30, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (\"Ainos\" or the \"Company\")\ntoday announced that it has completed the required data delivery and\ntechnology transfer under its VELDONA® license agreement, triggering a\n$600,000 initial license payment. The licensing partner confirmed completion\nin writing on September 29. Payment is due within 15 business days under the\nagreement.\n\nThe delivery includes clinical and regulatory materials for Sjögren's disease\nand thrombocytopenia, providing a foundation for the partner's continued\ndevelopment work in autoimmune and hematologic diseases. The initial payment\nis part of the previously announced potential $10 million licensing framework,\nwhich also includes conditional payments tied to the first sublicense and\nlicenses for 15 additional indications. Ainos is separately entitled to 25% of\nnet sublicensing revenue, as defined in the agreement.\n\n\"We are delivering on the commitments we have communicated to shareholders,\"\nsaid Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos.\n\"Following the delivery of 1,400 AI Nose systems to ASE, completion of the\nVELDONA technology transfer marks another tangible step in executing our\nagreements and realizing value from our assets. Our priorities remain clear:\nfulfill our commitments, collect contractual payments and allocate resources\nprudently as we advance Chemical Intelligence commercialization.\"\n\nForward-Looking Statements\n\nCertain statements in this press release are forward-looking statements within\nthe meaning of Section 27A of the Securities Act of 1933, as amended, and\nSection 21E of the Securities Exchange Act of 1934, as amended. All statements\nother than statements of historical fact are forward-looking statements.\nForward-looking statements are based on management's current assumptions and\nexpectations of future events and trends, which affect or may affect the\nCompany's business, strategy, operations or financial performance, and actual\nresults and other events may differ materially from those expressed or implied\nin such statements due to numerous risks and uncertainties. Forward-looking\nstatements are inherently subject to risks and uncertainties, some of which\ncannot be predicted or quantified. There are a number of important factors\nthat could cause actual results, developments, business decisions or other\nevents to differ materially from those contemplated by the forward-looking\nstatements in this press release. These factors include, among other things,\nthe uncertainty of the contemplated collaboration framework and the expected\nreceipt of license fees, manufacturing license fees and other consideration\nthereunder; our expectation that we will incur net losses for the foreseeable\nfuture; our ability to become profitable; our ability to raise additional\ncapital to continue our product development; our ability to accurately predict\nour future operating results; our ability to advance our current or future\nproduct candidates through clinical trials, obtain marketing approval and\nultimately commercialize any product candidates we develop; the ability to\nobtain and maintain regulatory approval of our licensed indications and\nproduct candidates; delays in completing the development and commercialization\nof our current and future product candidates; developing and commercializing\nadditional products, including diagnostic testing devices; our ability to\ncompete in the marketplace; compliance with applicable laws, regulations and\ntariffs, and factors described in the Risk Factors section of our public\nfilings with the Securities and Exchange Commission (SEC). Because\nforward-looking statements are inherently subject to risks and uncertainties,\nyou should not rely on these forward-looking statements as predictions of\nfuture events. These forward-looking statements speak only as of the date of\nthis press release and, except to the extent required by applicable law, the\nCompany undertakes no obligation to update or revise these statements, whether\nas a result of any new information, future events and developments or\notherwise.\n\nInvestor Relations\nir@ainos.com\n\nSOURCE: Ainos, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/ainos-completes-veldona-technology-transfer-triggering%c2%a0600-0-1228909)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSs0dTza-20260930","title":"Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment","author":"ACCESSWIRE","ticker":"AIMD","created":"2026-09-30T13:00:01.168Z","tickers":["AIMD","AIMDW"],"exchange":"NASDAQ","article_body":"HOUSTON, TX / ACCESS Newswire (https://www.accessnewswire.com/) / September\n30, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (\"Ainos\" or the \"Company\")\ntoday announced that it has completed the required data delivery and\ntechnology transfer under its VELDONA® license agreement, triggering a\n$600,000 initial license payment. The licensing partner confirmed completion\nin writing on September 29. Payment is due within 15 business days under the\nagreement.\n\nThe delivery includes clinical and regulatory materials for Sjögren's disease\nand thrombocytopenia, providing a foundation for the partner's continued\ndevelopment work in autoimmune and hematologic diseases. The initial payment\nis part of the previously announced potential $10 million licensing framework,\nwhich also includes conditional payments tied to the first sublicense and\nlicenses for 15 additional indications. Ainos is separately entitled to 25% of\nnet sublicensing revenue, as defined in the agreement.\n\n\"We are delivering on the commitments we have communicated to shareholders,\"\nsaid Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos.\n\"Following the delivery of 1,400 AI Nose systems to ASE, completion of the\nVELDONA technology transfer marks another tangible step in executing our\nagreements and realizing value from our assets. Our priorities remain clear:\nfulfill our commitments, collect contractual payments and allocate resources\nprudently as we advance Chemical Intelligence commercialization.\"\n\nForward-Looking Statements\n\nCertain statements in this press release are forward-looking statements within\nthe meaning of Section 27A of the Securities Act of 1933, as amended, and\nSection 21E of the Securities Exchange Act of 1934, as amended. All statements\nother than statements of historical fact are forward-looking statements.\nForward-looking statements are based on management's current assumptions and\nexpectations of future events and trends, which affect or may affect the\nCompany's business, strategy, operations or financial performance, and actual\nresults and other events may differ materially from those expressed or implied\nin such statements due to numerous risks and uncertainties. Forward-looking\nstatements are inherently subject to risks and uncertainties, some of which\ncannot be predicted or quantified. There are a number of important factors\nthat could cause actual results, developments, business decisions or other\nevents to differ materially from those contemplated by the forward-looking\nstatements in this press release. These factors include, among other things,\nthe uncertainty of the contemplated collaboration framework and the expected\nreceipt of license fees, manufacturing license fees and other consideration\nthereunder; our expectation that we will incur net losses for the foreseeable\nfuture; our ability to become profitable; our ability to raise additional\ncapital to continue our product development; our ability to accurately predict\nour future operating results; our ability to advance our current or future\nproduct candidates through clinical trials, obtain marketing approval and\nultimately commercialize any product candidates we develop; the ability to\nobtain and maintain regulatory approval of our licensed indications and\nproduct candidates; delays in completing the development and commercialization\nof our current and future product candidates; developing and commercializing\nadditional products, including diagnostic testing devices; our ability to\ncompete in the marketplace; compliance with applicable laws, regulations and\ntariffs, and factors described in the Risk Factors section of our public\nfilings with the Securities and Exchange Commission (SEC). Because\nforward-looking statements are inherently subject to risks and uncertainties,\nyou should not rely on these forward-looking statements as predictions of\nfuture events. These forward-looking statements speak only as of the date of\nthis press release and, except to the extent required by applicable law, the\nCompany undertakes no obligation to update or revise these statements, whether\nas a result of any new information, future events and developments or\notherwise.\n\nInvestor Relations\nir@ainos.com\n\nSOURCE: Ainos, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/ainos-completes-veldona-technology-transfer-triggering%c2%a0600-0-1228909)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-09-30T13:00:02.899231351Z","server_sent_at_ms":1790773202899},"received_at":"2026-09-30T13:00:02.950Z","source_url":"https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/ainos-completes-veldona-technology-transfer-triggering%c2%a0600-0-1228909"},"analysis":{"id":"145463","press_release_id":"156787","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["company expects net losses for the foreseeable future and may need additional capital","conditional payments and license fee receipt remain subject to uncertainty per forward-looking statements"],"eventType":"operations_update","narrative":"Ainos completed the required data delivery and technology transfer under its VELDONA license agreement, with the licensing partner confirming completion in writing on September 29.\n\nThe completion triggers a $600,000 initial license payment due within 15 business days, part of a previously announced potential $10 million licensing framework that includes conditional payments tied to a first sublicense and 15 additional indications.\n\nAinos is also entitled to 25% of net sublicensing revenue; the milestone follows delivery of 1,400 AI Nose systems to ASE and marks continued execution of the company's licensing and commercialization agenda.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Small-cap cash milestone: $600K license payment triggered as Ainos executes on its $10M VELDONA licensing framework."},"keyFigures":{"dealValueUsd":10000000,"customDimensions":{"payment_deadline_days":"15 business days","additional_indications":15,"ai_nose_systems_delivered":1400,"license_payment_triggered":600000,"sublicensing_revenue_share":"25% of net sublicensing revenue"}},"quotedText":"Following the delivery of 1,400 AI Nose systems to ASE, completion of the VELDONA technology transfer marks another tangible step in executing our agreements and realizing value from our assets.","namedEntities":{"people":[{"name":"Eddy Tsai","role":"Chairman, President and CEO"}],"products":["VELDONA","AI Nose"],"companies":[{"name":"Ainos, Inc.","ticker":"AIMD","relationship":"filer/licensor"},{"name":"ASE","relationship":"customer"}],"dollarAmounts":[{"amount":"$600,000","context":"initial license payment triggered by technology transfer"},{"amount":"$10 million","context":"previously announced potential licensing framework"},{"amount":"25%","context":"share of net sublicensing revenue"}]},"materialImpact":{"score":2,"reasoning":"Completion of a contractual technology transfer triggers a modest $600,000 payment within a previously announced $10M licensing framework. Positive cash-relevant milestone but small in absolute terms for the filer."},"tickerRelevance":{"others":[],"primary":"AIMD"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"contractual milestone with modest cash impact","householdBrandBoost":false,"retailFavoriteBoost":false}},"event_type":"operations_update","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":2,"narrative":"Ainos completed the required data delivery and technology transfer under its VELDONA license agreement, with the licensing partner confirming completion in writing on September 29.\n\nThe completion triggers a $600,000 initial license payment due within 15 business days, part of a previously announced potential $10 million licensing framework that includes conditional payments tied to a first sublicense and 15 additional indications.\n\nAinos is also entitled to 25% of net sublicensing revenue; the milestone follows delivery of 1,400 AI Nose systems to ASE and marks continued execution of the company's licensing and commercialization agenda.","key_figures":{"dealValueUsd":10000000,"customDimensions":{"payment_deadline_days":"15 business days","additional_indications":15,"ai_nose_systems_delivered":1400,"license_payment_triggered":600000,"sublicensing_revenue_share":"25% of net sublicensing revenue"}},"named_entities":{"people":[{"name":"Eddy Tsai","role":"Chairman, President and CEO"}],"products":["VELDONA","AI Nose"],"companies":[{"name":"Ainos, Inc.","ticker":"AIMD","relationship":"filer/licensor"},{"name":"ASE","relationship":"customer"}],"dollarAmounts":[{"amount":"$600,000","context":"initial license payment triggered by technology transfer"},{"amount":"$10 million","context":"previously announced potential licensing framework"},{"amount":"25%","context":"share of net sublicensing revenue"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T13:00:10.890Z","global_importance":18,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap","eventGravity":"contractual milestone with modest cash impact","householdBrandBoost":false,"retailFavoriteBoost":false}},"durationMs":6236,"modelName":"glm-5.3-flashx"}}